drugset / Trial / NCT03189537

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

NCT03189537 ↗

Phase 3 Completed 400 enrolled Valenta Pharm JSC
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections

Timeline

Start
2010-10-03
Primary completion
2011-04-19
Completion
2011-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ingavirin Small molecule 90 mg Oral

Indications